Ian Collins,John Jamieson Caldwell,Antony William Oliver,Tony Michael Raynham,Emma Jane Welsh,Cornelius Albertus Johannes Matijssen
申请号：
US12738808
公开号：
US08324226B2
申请日:
2008.10.23
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor (b) a DNA damaging agent (c) an antimetabolite or TS inhibitor (d) a microtubule targeted agent and (e) ionising radiation.
